MC-Val-Cit-PAB-MMAF is a key component in antibody-drug conjugates (ADCs) used for cancer therapy. It combines a potent drug with a cleavable linker, ensuring precise delivery to cancer cells.
Key Components:
- MC (Maleimidocaproyl): Anchors the drug-linker to antibodies via cysteine, enhancing stability.
- Val-Cit (Valine-Citrulline Dipeptide): A protease-sensitive linker that releases the drug inside tumor cells.
- PAB (Para-aminobenzyl alcohol): Acts as a spacer, aiding in the controlled release of the drug.
- MMAF (Monomethyl Auristatin F): A powerful cytotoxic agent that disrupts tubulin, stopping cancer cell growth.
Applications:
- Antibody-Drug Conjugates: Delivers MMAF directly to cancer cells, reducing harm to healthy tissue.
- Cancer Therapy: Enhances targeted action and minimizes side effects.
Benefits:
- Targeted Delivery: Focuses the cytotoxic effect on tumor cells.
- Precise Release: Cleavable linker ensures the drug activates inside the cancer cell.
- High Potency: MMAF effectively kills cancer cells at low doses.
MC-Val-Cit-PAB-MMAF supports the development of precise cancer treatments, boosting efficacy and reducing systemic toxicity.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
